Market capitalization in Taiwan’s biotech sector is currently being propelled by three core drivers: clinical trial progress, revenue growth, and capacity expansion. While PharmaEssentia remains a leader, companies like Pell Bio-Med Technology, LinBio, Bora, and Lotus are emerging as the next valuation frontrunners.
- Bora Pharmaceuticals: Driven by a dual "Branded Generic + CDMO" engine. The company is increasing capital for its Maple Grove plant in Minnesota to secure high-potential projects. Its subsidiary, Tanvex-KY, has completed two 2,000L single-use bioreactor lines and is progressing with the FDA resubmission for its biosimilar, TX05.
- Lotus Pharmaceutical: Following significant M&A and overseas expansion, Lotus has completed the closing of four products in a Vietnam portfolio deal, with sales starting in Q1. It remains a top contender for the industry’s revenue crown.
- Pell Bio-Med Technology Biomedical: Leveraging the new Regenerative Medicine Act, its multi-chain Mesothelin CAR-T platform for solid tumors aims for human trials next year. Additionally, its short-chain peptide PP011 for rheumatoid arthritis has garnered market interest due to unexpected weight-loss effects in animal studies.
- LinBio (Belite Bio): Focus remains on LBS-008 for adolescent Stargardt disease. The DRAGON II Phase 2/3 trial has completed enrollment of 60 subjects across Japan, the U.S., and the UK. An NDA filing with the U.S. FDA is planned for H1 2026.
- Heron Neutron Medical: Continues to lead in AB-BNCT (Accelerator-Based Boron Neutron Capture Therapy), having secured TFDA medical device certification for its neutron irradiation system.
Resource: 生技業三箭齊發 各擁題材
